Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

被引：10
|
作者：
Ayyappan, Sabarish [1 ]
Kim, Won Seog [2 ]
Kim, Tae Min [3 ]
Walewski, Jan [4 ]
Cho, Seok-Goo [5 ]
Jarque, Isidro [6 ]
Iskierka-Jazdzewska, Elzbieta [7 ]
Poon, Michelle [8 ]
Oh, Sung Yong [9 ]
Lim, Francesca Lorraine Wei Inng [10 ]
Carpio, Cecilia [11 ]
Tan, Tran-Der [12 ]
Gutierrez, Antonio [13 ]
Zhang, Huilai [14 ]
Cao, Junning [15 ]
Zhang, Mingzhi [16 ,17 ]
Tessoulin, Benoit [18 ,19 ]
Li, Jingjin [20 ]
Ufkin, Melanie [20 ]
Shariff, Saleem [21 ]
Chi, Lei [20 ]
Chaudhry, Aafia [20 ]
Mohamed, Hesham [20 ]
Ambati, Srikanth [20 ]
Prince, H. Miles [22 ,23 ]
机构：
[1] Univ Iowa Hosp & Clin, Iowa City, IA USA
[2] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[4] Marii Sklodowskiej Curie Panstwowy Inst Badawczy, Narodowy Inst Onkol, Warsaw, Poland
[5] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[6] Hosp Univ La Fe, Valencia, Spain
[7] Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland
[8] Natl Univ Canc Inst, Dept Haematol Oncol, Singapore, Singapore
[9] Dong A Univ Hosp, Busan, South Korea
[10] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore
[11] Autonomous Univ Barcelona UAB, Univ Hosp Vall Hebron, Barcelona, Spain
[12] Koo Fdn, Sun Yat Sen Canc Ctr, Taipei, Taiwan
[13] Hosp Univ Son Espases, IdISBa Palma, Palma De Mallorca, Spain
[14] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[15] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[16] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[17] Lymphoma Diag & Treatment Ctr Henan Prov, Zhengzhou, Peoples R China
[18] Nantes Univ, Sch Med, Nantes, France
[19] Univ Hosp Nantes, Nantes, France
[20] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[21] Regeneron UK Ltd, Uxbridge, England
[22] Epworth Healthcare, Melbourne, Australia
[23] Univ Melbourne, Melbourne, Australia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179818
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Zhang, Huilai
    Cheng, Ying
    Yang, Haiyan
    Zhang, Liling
    Zou, Liqun
    Guo, Ye
    Cao, Junning
    Huang, Huiqiang
    Wang, Zhao
    Huang, Sha
    Liang, Zhiyu
    Lyu, Jiaoyan
    Fang, Yiqian
    Cohen, Aileen
    Zhou, Keshu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL)
    Borchmann, P.
    Bachanova, V.
    Westin, J.
    Tam, C.
    Jaeger, U.
    McGuirk, J.
    Holte, H.
    Waller, E.
    Jaglowski, S.
    Bishop, M.
    Andreadis, C.
    Foley, S. R.
    Fleury, I.
    Teshima, T.
    Mielke, S.
    Salles, G.
    Ho, J.
    Izutsu, K.
    Maziarz, R.
    van Besein, K.
    Kersten, M. J.
    Wagner-Johnston, N.
    Kato, K.
    Corradini, P.
    Han, X.
    Agoulnik, S.
    Chu, J.
    Eldjerou, L.
    Pacaud, L.
    Schuster, S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 238 - 238
  • [33] Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
    Villasboas, Jose. C.
    Kim, Tae Min
    Taszner, Michal
    Novelli, Silvana
    Cho, Seok-Goo
    Merli, Michele
    Ubieto, Ana Jimenez
    Tessoulin, Benoit
    Poon, Michelle
    Walewski, Jan
    Yi, Shuhua
    Song, Yuqin
    Chong, Geoffrey
    Luminari, Stefano
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu
    Jagadeesh, Deepa
    Zhang, Wei
    Magnano, Laura
    Iskierka-Jazdzewska, Elzbieta
    Tani, Monica
    Cai, Jessica
    Uppala, Amulya
    Shariff, Saleem
    Chi, Lei
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Tucker, David
    [J]. BLOOD, 2023, 142
  • [34] Grading of Neurotoxicity in Patient with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study
    Maziarz, Richard T.
    Schuster, Stephen J.
    Romanov, Vadim V.
    Rusch, Elisha S.
    Signorovitch, James
    Ericson, Solveig G.
    Maloney, David G.
    Locke, Frederick L.
    [J]. BLOOD, 2018, 132
  • [35] Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 33 - 33
  • [36] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
    Martin Garcia-Sancho, A.
    Baile, M.
    Rodriguez, G.
    Dlouhy, I.
    Sancho, J. M.
    Jarque, I.
    Gonzalez-Barca, E.
    Salar, A.
    Espeso, M.
    Grande, C.
    Bergua, J.
    Montes-Moreno, S.
    Redondo, A.
    Enjuanes, A.
    Campo, E.
    Lopez-Guillermo, A.
    Caballero, D.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
  • [37] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
    Duell, Johannes
    Jurczak, Wojciech
    Liberati, Anna Marina
    Halka, Janusz
    Carbo, Esther Pena
    Costa, Pau Abrisqueta
    Maddocks, Kami J.
    Dreyling, Martin
    Rosenwald, Andreas
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles
    [J]. BLOOD, 2022, 140 : 6596 - 6598
  • [39] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
    de Vos, Sven
    Reagan, Patrick M.
    Patel, Manish R.
    Saba, Nakhle S.
    Mortlock, Andrew
    Cerec, Virginie
    Munugalavadla, Veerendra
    Acar, Melih
    Nuttall, Barrett
    Jenkins, David
    White, Rafael
    Callahan, Megan
    Forcina, Alessandra
    Roschewski, Mark
    Flinn, Ian W.
    [J]. BLOOD, 2022, 140 : 6635 - 6637
  • [40] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
12345